Scinai Immunotherapeutics Ltd. operates as an emerging biopharmaceutical company, dedicated to the research, production, and market introduction of medical solutions. Based in Israel, its primary objective is the prevention and treatment of a range of infectious, autoimmune, and other health conditions. The company maintains a significant licensing and collaboration agreement with the Max Planck Society and the University Medical Center Göttingen. This partnership is focused on advancing and commercializing a nanosized antibody (NanoAb) specifically for COVID-19, in addition to pursuing…
WATCHLIST OCT 13 2026 Benzinga PreMarket Gainers (% change and volume) $PFAI $TCRT $AIXI $SCNI $FCHL $BKYI $YJ $MUZ Read our Benzinga Review here: https://t.co/DbZGLBN9ND https://t.co/5ZWs5fDKrf
Consensus price target: $700.00 (+158630.16% upside from $0.44)
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $1.31M | +99.24% | $-8.31M |
| 2024 | $658K | — | $4.8M |
| 2023 | $0 | — | $-6.5M |
Stock data for SCNI: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics